Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul J. Schmidt is active.

Publication


Featured researches published by Paul J. Schmidt.


Annals of Internal Medicine | 1972

Posttransfusion Hepatitis After Exclusion of Commercial and Hepatitis-B Antigen-Positive Donors

Harvey J. Alter; Paul V. Holland; Robert H. Purcell; Jerrold J. Lander; Stephen M. Feinstone; Andrew G. Morrow; Paul J. Schmidt

Abstract In a prospective study the exclusion of commercial blood donors and donors positive for hepatitis-B antigen (HBAg) resulted in a hepatitis frequency of only 3.7 cases/1000 units transfused...


The New England Journal of Medicine | 2002

Blood and disaster: Supply and demand

Paul J. Schmidt

Almost immediately after the attacks that struck New York City and Washington, D.C., on September 11, 2001, the federal government and the American Red Cross issued an appeal for blood donors. Nati...


Transfusion | 1962

Febrile, Nonhemolytic Transfusion Reactions and the Limited Role of Leukoagglutinins in Their Etiology

Sherwin V. Kevy; Paul J. Schmidt; Mary H. McGinniss; William G. Workman

In more than ten thousand transfusions given over a four‐year period to 1,649 patients, the incidence of urticarial reactions was 1.1 per cent. There were no hemolytic transfusion reactions and none due to bacterial contamination or to bacterial pyrogens. There were 276 “Febrile Nonhemolytic” reactions for an incidence of 2.5 per cent.


The New England Journal of Medicine | 1966

Isoimmunization after Multiple Transfusions

Mary M. Lostumbo; V. Holland; Paul J. Schmidt

THE risk of isoimmunization after blood transfusion depends on the relative frequency of blood-group factors, their antigenicity and the number and timing of exposures (transfusions). There have be...


The New England Journal of Medicine | 1959

A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia.

Emil J. Freireich; Paul J. Schmidt; Marvin A. Schneiderman; Emil Frei

GROSS bleeding is a frequent and major complication in patients with acute leukemia. The etiology of this bleeding is closely related to thrombocytopenia,1 although other coagulation abnormalities ...


Transfusion | 2012

The plasma wars: a history

Paul J. Schmidt

P lasma, the first blood component, was born in conflict 75 years ago. It was first produced for World War II, a conflict dubbed “The Plasma War,” amid conflicting views as to whether it should be provided as a liquid or a dried powder. Near the end of the war, when the necessary collection, refrigeration, and air transport links had been established, whole blood was shipped to the battlefront and found to be superior. The American National Red Cross collected more than 13 million units of blood between 1942 and 1945; more than 12 million were converted into plasma, the red blood cells (RBCs) mostly discarded. By the end of the war, more than 40,000 pints of whole blood were used in the final battle for Okinawa. History of human progress is really biography and the plasma story of liquid versus dried is the story of two men, John Elliott and Max Strumia. In the 60 years since then, Plasma Wars continue as only scientific skirmishes with suggested revisions in processing or usage found almost monthly in the current literature.


Transfusion | 1972

Hepatitis B Antigen (HB Ag) and Antibody (Anti-HB Ag) in Cold Ethanol Fractions of Human Plasma

Paul V. Holland; Harvey J. Alter; Robert H. Purcell; Lander Jj; Sgouris Jt; Paul J. Schmidt

Hepatitis B Antigen (HB Ag) has been found in human blood capable of transmitting viral hepatitis. HB Ag and anti‐HB Ag were therefore sought in the cold ethanol fractions of plasma from HB Ag+ patients collected into three different anticoagulant solutions, in fractions from individuals with anti‐complementary plasma containing anti‐HB Ag, and in fractions from large pools of ACD plasma from normal blood donors. HB Ag was present in all Cohn fractions except Fraction II (immune serum globulin, ISG) when prepared from HB Ag+ plasma regardless of the anticoagulant used. Five of eleven production lots of ISG and one of six NSA preparations contained measurable quantities of anti‐HB Ag, but none contained HB Ag.


Vox Sanguinis | 1959

A second example of the blood type "rhG".

Sherwin V. Kevy; Paul J. Schmidt; Webster C. Leyshon

A second example is reported of a blood that is rh′ (C) negative and Rho (D) negative while reacting strongly with anti‐Rho′ (CD) serum.


Vox Sanguinis | 1965

DIFFERENCES BETWEEN ANTI-H AND ANTI-OI RED CELL ANTIBODIES.

Paul J. Schmidt; Mary H. McGinniss

Both anti-0 and anti-H reagents preferentially agglutinate human group 0 red cells. When this activity is inhibited by H substance (secretor saliva) the serum is said t o contain anti-H; conversely, if not inhibited the serum is said to be anti-0 [7]. The recognition of anti-0 as separate from anti-H sera is of considerable theoretical importance in the search for the determinants of blood group specificity. Also, we have commented on this difference as being of practical importance in blood transfusion [4]. There is evidence that anti-0 destroys group 0 red cells in vivo and anti-H does not. The I blood group system has bearing on specificity in the ABO system. GOLD has described parallels between anti-0, anti-A,, and anti-I [2]. We have examined the relationship between anti-H and anti-I and contrasted this with anti-0 by serologic and in vivo compatibility studies.


Transfusion | 2003

Evaluation of Bacterial Contamination in Blood Processing

R. J. Elin; W. B. Lundberg; Paul J. Schmidt

In the routine deglycerolization of frozen red blood cells, a bottle of solution intended as a final wash (0.8% NaCI, 0.2% dextrose) was found to be abnormally colored and slightly turbid. Close inspection revealed a small crack in the base of the bottle. A pure growth of Klebsiella pneumoniae was cultured. The rabbit pyrogen test on the solution was positive using 2.5 μl as was the limulus amebocyte lysate (LAL) test at a dilution of 1:105 for endotoxin. Studies of the growth of this organism are described and the clinical implications are discussed.

Collaboration


Dive into the Paul J. Schmidt's collaboration.

Top Co-Authors

Avatar

Mary H. McGinniss

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Webster C. Leyshon

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Andrew G. Morrow

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Harvey J. Alter

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mary M. Lostumbo

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Robert H. Purcell

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sherwin V. Kevy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

E.G. Morrison

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

George Brecher

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge